Fast Track Group FTRK 深 滬
已收盤 01-09 16:00:00 美东时间
0.82
-0.057
-6.51%
華盛通- 最 高0.877
- 今 開0.8529
- 成交量 2.00万股
- 最 低 0.8124
- 昨 收 0.8771
- 總市值 1788.63万
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 0.09%
- 52周最低 0.2916
- 委 比 -87.27%
- 總股本 2181.25万
- 歷史最高 9.69
- 量 比 0.10
- 振 幅 7.37%
- 歷史最低 0.2916
- 每 手 1
- 風險率 1.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics reported preliminary 2025 financial results, including U.S. net product sales of $156 to $160 million, a 35-38% increase from 2024, and total revenue of $400 to $408 million, a 20-23% rise. Cash reserves reached approximately $168 million. Q4 retail prescription equivalents grew 34% year-over-year. The company introduced Vision 2040, aiming to expand its cardiometabolic franchise and rare disease pipeline. Operating expenses...
01-11 23:00
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Barbara Weber, M.D., founder and CEO of Tango Therapeutics, has retired as CEO and will serve as Executive Chair in 2026, transitioning to non-executive chair in 2027. Malte Peters, M.D., a board member since 2018, has been appointed President and CEO. Weber will support the company’s strategic priorities and ensure a smooth transition with Peters. The company has also updated its 2026 clinical milestones, including trials for vopimetostat and TN...
01-08 14:05
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
Annexon, Inc. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart to treat Guillain-Barré syndrome (GBS). The drug, a first-in-class antibody, aims to rapidly block neuroinflammation and improve recovery for GBS patients, who currently have limited treatment options. Regulatory submissions in the U.S. are planned for 2026.
01-08 13:00
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
BioVie Inc. has completed enrollment of 60 patients in its Phase 2 SUNRISE-PD trial evaluating bezisterim for early-stage Parkinson’s disease. The trial aims to assess whether bezisterim can delay disease progression and improve symptoms. It uses a decentralized design to enhance accessibility. Topline results are expected in the first half of 2026.
01-08 13:00
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
<p>Cullinan Therapeutics provided an update on its 2026 milestones, including CLN-978 data readouts across autoimmune indications, CLN-049 dosing expansion for AML, and Zipalertinib's rolling NDA submission. The company also reported a cash position of $439.0 million as of December 31, 2025, with runway into 2029. These developments highlight progress in autoimmune diseases and oncology programs.</p>
01-08 12:00
NervGen Pharma Begins Trading on Nasdaq Today
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. announced its common shares are now listed on Nasdaq under the symbol "NGEN." Adam Rogers, NervGen's Interim CEO, stated that the listing enhances market visibility, liquidity, and shareholder base, supporting long-term value as the company advances NVG-291, a neuroreparative peptide, toward becoming the first approved pharmacologic therapy for spinal cord injury ...
01-08 11:30
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies reports progress in the TSHA-102 pivotal program for Rett syndrome. First patient dosed in the REVEAL trial (Q4 2025), with enrollment ongoing across multiple sites. Written alignment with FDA to include ≥3 months of ASPIRE trial safety data in BLA submission for a broad label in patients ≥2 years. Dosing completion in REVEAL and ASPIRE trials expected Q2 2026, with long-term data update from REVEAL Part A in H1 2026. TSHA-1...
01-06 13:00
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Altimmune's pemvidutide has received FDA Breakthrough Therapy Designation for treating metabolic dysfunction-associated steatohepatitis (MASH) based on phase 2b data showing significant liver improvements. Phase 3 trial parameters are aligned with FDA, with plans to evaluate multiple doses over 52 weeks.
01-05 12:30
Tango Therapeutics Appoints Sung Lee to Board of Directors
Tango Therapeutics appoints Sung Lee to its Board of Directors. Lee brings over 20 years of finance leadership experience in biopharma and tech. As CFO of companies like Cytokinetics and Vir Biotechnology, Lee has a strong track record in corporate strategy and investor relations. His expertise will support Tango’s lead program, vopimetostat, advancing into registrational studies and late-stage clinical development.
01-05 12:00
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel
Scilex Holding Company appoints Kasowitz LLP and Marc Kasowitz as litigation and intellectual property counsel to strengthen its legal capabilities, particularly incomplex commercial and patent litigation, as it advances and protects its proprietary pharmaceutical assets. Kasowitz is a veteran U.S. trial lawyer with extensive experience in intellectual property disputes, particularly in life sciences. Scilex Holding, based in Palo Alto, Calif., f...
01-02 14:00
